CompletedPhase 3

A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C

South Korea156 participantsStarted 2024-04-17

Plain-language summary

The purpose of this clinical trial is to evaluate the efficacy and safety of co-administrated BR1018B and BR1018C in patients with essential hypertension and primary hypercholesterolemia

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Naïve : 140 mmHg ≤ MSSBP \< 180 mmHg and MSDBP \< 110 mmHg
✓. Use antihypertensive drugs : 130 mmHg ≤ MSSBP \< 180 mmHg and MSDBP \< 110 mmHg

What they're measuring

Mean sitting systolic blood pressure

Timeframe: 8weeks from Baseline Visit

LDL-C

Timeframe: 8weeks from Baseline Visit

Trial details

NCT IDNCT06165250

SponsorBoryung Pharmaceutical Co., Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-11-11

View on ClinicalTrials.gov More Essential Hypertension trials